Mutant p53 frequently accumulates in cancer cells and promotes tumor cell invasion, as part of its gain of function. Its accumulation is partially due to enhanced stability, but little is known about how the mRNA levels of mutant p53 can be regulated. Likewise, the impact of cancer therapy on the levels of mutant p53 is poorly understood. We show here that the anthracyclines doxorubicin, daunorubicin and epirubicin further increase the amounts of mutant p53 mRNA and protein in cancer cells. Moreover, we show for the first time that the transcription factor E2F1 associates with the promoter DNA of TP53. Upon genotoxic treatment, E2F1 contributed to the expression of mutant p53, both directly and through induction of TAp73. In contrast, the anthracycline idarubicin and also another topoisomerase inhibitor, etoposide, failed to increase the levels of p53 mRNA, despite their ability to induce the synthesis of TAp73 mRNA. Instead, a natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide, but only less so by the other anthracyclines under study. RNA corresponding to the first exon of WRAP53 was mainly found in cell nuclei and it reduced the levels of mutant p53. Taken together, this suggests a reciprocal activation pattern of TP53 and WRAP53 by different chemotherapeutics. Reducing the levels of mutant p53 by small-interfering RNA increased chemosensitivity, and idarubicin prevented cell survival more efficiently than the mutant p53-inducing doxorubicin. We conclude that even closely related anthracyclines induce the synthesis of different, opposing transcripts from the TP53 locus. When using these drugs for cancer therapy, the increased levels of mutant p53 may augment its gain of function and thus favor unwanted chemoresistance and tumor progression.
Introduction
The tumor suppressor p53 is mutant in about half of all human malignancies. Most of these mutations lead to the synthesis of a full-length protein carrying a substitution at a single residue, with two important consequences: firstly, p53 loses its ability to bind the DNA of growth-suppressive promoters and thus fails to activate the adjacent genes. Secondly, mutant p53 accumulates to levels that by far exceed those of wildtype p53. The mechanisms of this accumulation include, but may not be limited to, enhanced protein stability. The failure of mutant p53 to induce its antagonist Mdm2 contributes to this stabilization, as Mdm2 normally promotes p53 degradation through its ubiquitin ligase activity. However, the mutation of p53 alone does not always result in p53 accumulation (Terzian et al., 2008) . Thus, additional mechanisms, on top of missing Mdm2 induction, lead to the high levels of mutant p53 in tumors. One response that is triggered by a large variety of chemotherapeutics consists in the posttranslational modifications of p53. Upon therapyinduced DNA damage, wild-type p53 is phosphorylated and acetylated, leading to increased protein stability and transcriptional activity (Bode and Dong, 2004) . Although this mode of activation has been widely studied for wild-type p53, less is known about how chemotherapy affects the levels and activities of mutant p53.
Mutant p53 not only fails to carry out the tumorsuppressive functions of wild-type p53 (loss of function). In addition, accumulating evidence suggests that mutant p53 can function in an oncogenic manner, through a gain of function. The consequences of mutant p53 accumulation include increased chemoresistance and enhanced ability to metastasize Lang et al., 2004; Di Agostino et al., 2006; Strano et al., 2007; Muller et al., 2009) . Thus, the accumulation of mutant p53 can be regarded as a major contribution to tumor progression. This raises the necessity to define the exact mechanisms that cause the rise in levels of mutant p53 seen in a majority of tumors.
Besides the increased stability of mutant p53 protein, until now a less addressed mechanism of p53 regulation concerns the corresponding mRNA levels. Especially for mutant p53, a protein that already acquired enhanced stability, mRNA regulation may be of greater importance for its overall levels than in the case of wild-type p53, in which feedback mechanisms rapidly adjust the protein turnover. A few studies were published to address how the synthesis of p53 mRNA is turned on by transcription factors (Raman et al., 2000; Wang and El-Deiry, 2006; Liu et al., 2007 Liu et al., , 2009 ). However, the exact impact of therapeutic regimens on p53 mRNA levels, especially in tumor cells that carry a p53 mutation, remains to be explored.
In addition to p53, its paralog p73 is also capable of inducing p53-responsive promoters. In tumors with p53 mutations, two mechanisms appear to link mutant p53 with p73: Firstly, mutant p53 was found in physical association with p73, attenuating p73-mediated transactivation Strano et al., 2000) . Secondly, the transcription of the TP53 gene (regardless of mutation) was found enhanced by the full-length p73 isoform TAp73 (Wang and El-Deiry, 2006 ). TAp73 expression is strongly induced by DNA damage, mainly through the activation of the transcription factor E2F1 Stiewe and Putzer, 2000) , and may thus function as a major mediator of tumor cell death in response to chemotherapy.
The TP53 gene locus encodes WD repeat containing, antisense to p53 (WRAP53), a partially overlapping transcript, antiparallel with respect to p53 mRNA. Ectopic WRAP53 expression was reported to regulate the levels of p53 mRNA (Mahmoudi et al., 2009) . Thus, the genomic region comprising TP53 contains an additional transcription start site, with overlapping mRNA synthesis running in opposite direction to p53.
Topoisomerase inhibitors are commonly subdivided into two broad classes, that is, inhibitors of topoisomerase I and those inhibiting topoisomerase II (Nitiss, 2009 ). However, even among the topoisomerase II inhibitors, comprising anthracyclines, etoposide, topotecan and others, different biochemical functions were characterized, possibly explaining why these drugs do not provide a uniform clinical spectrum of activities. These compound-specific biochemical functions include the efficiency and sequence specificity of drug intercalation with DNA, and they also pertain to the inhibition of topoisomerase II-induced ATP hydrolysis Robinson et al., 1993; Capranico et al., 1990 Capranico et al., , 1995 van Hille et al., 1999; Collins et al., 2001; Ju et al., 2006) . Among the topoisomerase II inhibitors, especially anthracyclines are widely used in the clinics. They include doxorubicin, daunorubicin, epirubicin and idarubicin. Notably, even these chemically related drugs display distinct clinical features, raising the possibility that their biochemical actions on the cell are also distinct (Minotti et al., 2004) . However, little is currently known about such differences in the mechanisms of action.
In this study, we show that cancer cells substantially increase their total amounts of mutant p53 in response to anthracyclines, through enhanced p53 mRNA synthesis. E2F1 binds to the TP53 promoter, and E2F1 is necessary, but not sufficient for, efficient p53 mRNA induction. Rather, substantial increases in p53 levels were only seen with a subset of anthracyclines, although all chemotherapeutics under the study augmented the expression of other E2F1 target genes. WRAP53 induction was observed mostly with those topoisomerase inhibitors that failed to upregulate p53 mRNA. Increased mutant p53, through its gain of function, may counteract the desired antitumor effects of some widely used anthracyclines.
Results
The expression levels of mutant p53 protein are elevated in response to doxorubicin Most tumor cell lines with mutations in TP53 accumulate high levels of the p53 protein. To assess whether chemotherapeutics can further increase these amounts, we performed immunoblot analyses and observed that the expression levels of p53 in the glioblastoma cell line U251 (p53 mutation R273H) were elevated even further upon treatment with the anthracycline doxorubicin ( Figure 1a ). Quantitative immunofluorescence microscopy was used to determine the expression levels of p53 in individual cells, as a function of treatment length and drug concentrations. This approach not only reveals the distribution of p53 levels in a cell population but also allows testing different drug concentrations and various incubation times in a 96-well format. The p53-derived fluorescence signal was measured for each nucleus of about 1000 cells per sample (Supplementary Figure  S1A) . We observed that the levels of p53 were increased significantly after treatment with doxorubicin ( Figure 1b ) and daunorubicin (Figure 1c) , as a function of drug concentration and time of treatment (Supplementary Figure S1B) . Similar effects were found in the breast cancer-derived cell line MDA-MB-231 (p53 mutation R280K) (Supplementary Figures S1C and D) .
Regarding the mechanisms behind this increase of mutant p53, we first tested the hypothesis that it may be a result of further protein stabilization, driven by posttranslational modifications. This hypothesis initially seemed plausible, as wild-type p53 is indeed stabilized through DNA damage-induced phosphorylations. Doxorubicin activates the DNA damage-responsive kinase ataxia telangiectasia mutated (Kurz et al., 2004) . It then phosphorylates wild-type p53 at serine 15, which in turn facilitates the acetylation of Lys 382 of p53 by the acetyl transferases p300 and Creb-binding protein. These modifications alleviate the Mdm2-mediated destabilization of wild-type p53 (Canman et al., 1998; Dumaz and Meek, 1999; Bode and Dong, 2004) . We therefore determined whether mutant p53 is posttranslationally modified in response to doxorubicin treatment, and whether this also increases protein stability. Indeed, after incubation with doxorubicin, mutant p53 was extensively phosphorylated at serine 15 and acetylated at lysine 382, as detected by modification-specific antibodies (Figure 1d ). Knockdown of Creb-binding protein, but not p300, severely decreased p53 acetylation (Figure 1e ), despite the knockdown efficiency of all small-interfering RNAs (siRNAs) under study (Supplementary Figure S1E) . Strikingly, however, this did not reduce the overall levels of mutant p53 in the Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein presence of doxorubicin (Figure 1e ). Of note, doxorubicin treatment did not increase the levels of Mdm2 in U251 cells, in contrast to the wild-type p53-containing U2OS cells (Supplementary Figure S1F) ; this may explain why acetylation at K382 is of no detectable importance in the accumulation of mutant p53, although acetylation increases the half-life of wild-type p53 (Ito et al., 2002) . p53 mRNA and protein levels are augmented in response to doxorubicin treatment, depending on the transcription factors E2F1 and TAp73.
Apart from stability, many proteins are regulated by changes in their corresponding mRNA levels. We tested this in the case of doxorubicin-mediated accumulation of mutant p53. Strikingly, quantitative real-time PCR analysis revealed 3-4 times more p53 mRNA upon doxorubicin treatment of U251 cells (Figure 2a) . Hence, doxorubicin increases the levels of mutant p53-encoding mRNA.
The activation of the transcription factor E2F1 upon DNA damage leads to the increased expression of proapoptotic target genes like TAp73 and Noxa (Hershko and Ginsberg, 2004; Urist et al., 2004) . Accordingly, p53 mRNA was elevated as strongly as TAp73 in response to doxorubicin (Figure 2a ). Corresponding increases in p53 and TAp73 mRNA were also observed in other cell lines with mutant p53, that is, A431 (p53 mutation R273H) and 5637 (p53 mutation R280T) cells Figure S1A , and depicted as histograms. The observed increase of mutant p53 levels was found to depend on the time of treatment as well as on the drug concentration (Supplementary Figure S1B) . A similar increase in response to doxorubicin or daunorubicin was observed in MDA-MB-231 cells (Supplementary Figures S1C and D) . (d) U251 cells were treated as in (a), followed by immunoblot analysis using modification-specific antibodies to acetyl-p53 and phospho-p53. The signals revealing acetylation of p53 at lysine 382 as well as phosphorylation at serine 15 were each found increased in response to doxorubicin treatment, to a degree that exceeded the overall increase of p53 levels (a), arguing that doxorubicin is capable of inducing these modifications on p53. (e) U251 cells were first transfected with siRNA to knockdown the acetyl transferases Creb-binding protein or p300, or transfected with control siRNA (negative control, NC) or siRNA to p53 (positive control). The cells were subsequently treated with doxorubicin as in (a). p53 acetylation (Ac-p53) was then detected by an antibody to Ac(K382) p53 as in (d), and global p53 levels were assessed in parallel. The knockdown efficiencies of the CBP and p300 siRNAs are displayed in Supplementary Figure S1E . Comparison of both blots revealed that reducing the amounts of CBP in the cells led to diminished p53 acetylation but did not reduce overall p53 levels.
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein The knockdown of E2F1 and TAp73 was found to be efficient (small diagrams) and each led to a reduction of p53 mRNA (a, d, black bars). E2F1 knockdown also reduced the levels of TAp73 (a, gray bars), as expected Stiewe and Putzer, 2000) .
(b) Total cell lysates were subjected to immunoblot analysis using antibodies against total p53, E2F1 and actin as loading control. Note a mild but detectable reduction in p53 levels when E2F1 was knocked down by siRNA. (c) Single-cell-based immunofluorescence analysis was used to determine the expression of p53. Means and s.d.'s of the triplicate analysis are diagramed in Supplementary Figure  S2B . For statistical analysis, a Student's t test was performed (a ¼ 0.05). Histogram representations of the p53 staining intensities obtained with control siRNA or siRNA #2 against E2F1 are shown here. A shift of the peak to the left indicates reduced p53 levels in response to E2F1 knockdown.
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein p53 in response to doxorubicin, arguing that this accumulation depends on transcription (Supplementary Figure S2C ). SiRNA-mediated knockdown revealed that the E2F1 target gene product TAp73 also contributes to the induction of p53 mRNA by doxorubicin (Figure 2d ), in agreement with a previous report (Wang and El-Deiry, 2006) . However, the knockdown of E2F1 reduced the amounts of p53 mRNA more profoundly than the knockdown of p73, whereas the expression levels of TAp73 were unequivocally lower in the latter case. Knocking down the previously described regulators of p53 transcription, HOXA5 (Raman et al., 2000) and RREB1 (Liu et al., 2009) , only slightly reduced the mRNA of p53 in U251 cells (Supplementary Figure  S2D) . We conclude that E2F1 contributes to the anthracycline-induced expression of mutant p53 by TAp73-dependent and -independent mechanisms.
E2F1 binds to the TP53 promoter region
We suspected a direct role for E2F1 in the induction of TP53. This was supported by a DNA binding consensus motif search using the Transfac algorithm (Matys et al., 2006) to predict evolutionary conserved potential E2F1 binding sites BS-I and BS-II, within the p53 promoter ( Supplementary Figures S3A and S3B ). Both sites were subjected to chromatin immunoprecipitation (ChIP) analysis to assess direct interaction with E2F1. It was found associated with BS-I, roughly 40 bp downstream of the transcription start site, but not within the second potential binding site BS-II (Figures 3a and b) . As expected, E2F1 also associated with the promoters of its target genes p107 and TAp73 (Figures 3c and d) . In contrast, the recovery of a more distant fragment at þ 19.5 kb from the TP53 transcription start site was at background level, similar to precipitation with nonspecific immunoglobulin G (Figure 3e ). Doxorubicin treatment did not detectably alter any of these DNAbinding characteristics of E2F1. This is compatible with the concept that genotoxic stress increases the strength of E2F1-mediated transactivation, for example, through posttranslational modifications of transactivation domains, but not necessarily through increased association with promoter DNA. In conclusion, E2F1 directly binds to a conserved DNA element near the transcription start site of TP53, providing a plausible explanation for the involvement of E2F1 in the doxorubicin-induced enhancement of p53 mRNA.
Chemotherapeutic drugs differentially induce mutant p53 levels
To test the specificity of p53 induction, we treated U251 cells with the topoisomerase I inhibitor camptothecin, the topoisomerase II inhibitor etoposide, as well as the nucleoside analog 5-fluorouracil (5 0 FU). All of these drugs failed to increase the p53 mRNA levels (Figure 4a ), although they were capable of inducing Noxa, another gene that is actively transcribed through E2F1 in response to genotoxic treatment (Hershko and Ginsberg, 2004) . Etoposide also induced TAp73, further arguing that it activates E2F1. We expected that both E2F1 and TAp73 should induce p53 transcription, as it was found in response to doxorubicin treatment. However, etoposide did not augment p53 mRNA. Hence, the induction of mutant p53 mRNA is specific to doxorubicin, rather than a general result of the DNA damage response and the accompanied activation of E2F1 and TAp73 evoked by most chemotherapeutics.
Etoposide treatment mediated an increase in serine 15 phosphorylation of p53 in U251 cells (Supplementary Figure S4A) presumably by activation of ataxia telangiectasia mutated (Canman et al., 1998; Tanaka et al., 2007) . Nevertheless, we observed in the same experiment that the total levels of p53 protein remain unchanged (Supplementary Figure S4B) . This argues that a nonspecific DNA damage response is insufficient to increase the levels of mutant p53 protein. Only doxorubicin showed this capability (Figure 1 ).
In addition to doxorubicin, other anthracyclines are currently used in the clinics, namely daunorubicin, epirubicin and idarubicin. These drugs are generally believed to function through intercalation with DNA and topoisomerase II inhibition. However, they display somewhat different sequence specificities for DNA intercalation (Minotti et al., 2004 ). These four abovenamed anthracyclines share a common four-membered ring system containing an anthraquinone chromophore with an aminoglycoside associated at the A-ring (C7), but they differ in the substitutions to this basic structure (Supplementary Figure S4C) .
Dauno-, doxo-and epirubicin induced p53 in a comparable manner; surprisingly, however, idarubicin, differing from daunorubicin only in a methoxy-group at C4 (D-ring), completely failed to do so. In contrast, all four compounds induced TAp73 (Figure 4b ). Correspondingly, all anthracyclines under study, except idarubicin, increased the amount of mutant p53 protein (Figure 4c ). Thus, idarubicin specifically lacks the capability of other anthracyclines to enhance the levels of p53 mRNA.
Next, we asked whether the induction of mutant p53 expression by doxorubicin but not by idarubicin also results in differential cell survival. We first tested the impact of mutant p53 on the survival of U251 cells upon doxorubicin treatment. The cells were first transfected with siRNA to p53 or control siRNA, followed by incubation with doxorubicin for 4 h. After removal of the drug, the cells were seeded in a 96-well imaging plate and further incubated. Their abundance was followed for 16 days with an imaging cytometer. The number of long-term surviving cells was found to be reduced upon knockdown of mutant p53, arguing that mutant p53 renders the cells more resistant to chemotherapy (Figure 4d) . Correspondingly, equimolar amounts of idarubicin decreased the number of surviving U251 cells more efficiently than doxorubicin (Figure 4d ). Taken together with the chemoprotective effect of mutant p53, it is tempting to speculate that the lack of mutant p53 induction is at least one reason for the enhanced cell killing efficiency of idarubicin, in comparison with doxorubicin.
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein WRAP53, an opposing transcript originating in the TP53 locus, is most strongly induced by topoisomerase inhibitors that fail to augment p53 mRNA The recent finding that p53 is regulated through a natural antisense transcript, WD repeat containing, antisense to p53 (WRAP53) (Mahmoudi et al., 2009) , prompted us to investigate whether the expression of this transcript responds to treatment with anthracyclines. WRAP53 was identified as a gene located immediately upstream of TP53 on the opposite strand of chromosome 17. At least 17 variants of this gene were identified, generated through alternative splicing as well as three different transcription start sites. So far, the reported function of the WRAP53 protein is without obvious relation to p53 (Mahmoudi et al., 2010) , but it has been reported that exon 1a of the WRAP53 mRNA contributes to the induction of p53 in response to DNA damage. In Figure 5a , the 10 transcripts listed in the Ensembl database were aligned with the TP53 gene. Two of the known transcripts (WRAP53-001 and WRAP53-203) contain exon 1a, which overlaps with a large portion of TP53, exon 1, in an antisense manner. We analyzed the expression of WRAP53 mRNA in response to anthracycline treatment, using three different primer pairs. Exons 7-8 were amplified to represent the majority of the WRAP53 transcripts. Primers corresponding to exon 1a or to exons 1a-2 were used to specifically amplify WRAP53 transcripts that overlap 
IP E2F1 IgG
Figure 3 E2F1 specifically binds to the predicted recognition site in the p53 promoter region. U251 cells were treated with 500 nM doxorubicin for 24 h. ChIP analysis was performed using antibodies against E2F1, or IgG as negative control. Quantitative RT-PCR was performed using primers that amplify the predicted (Supplementary Figure S3) E2F1 binding sites on TP53 (a, b), the previously described E2F1 binding sites on RBL1/p107 (c) and the TA promoter on TP73 (d), and a region 19.5 kb downstream of the transcriptional start site of TP53 (e). Note that nonspecific IgG precipitated different percentages of input DNA, perhaps reflecting the differential accessibility of distinct chromosomal regions. Only the E2F1 binding site I (BS-I, a) of TP53, but not BS-II (b) or a distant region of TP53 (e), was found to associate with E2F1 above this background. E2F1 binding was also observed for the RBL1/p107 (c) and the TP73 promoters (d). In each case, E2F1 association did not depend on doxorubicin, whereas E2F1-mediated transactivation was increased by the drug (Figure 2 ).
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein with p53 mRNA (Supplementary Figure S5A) . In response to doxorubicin, we observed a two-to threefold upregulation of WRAP53 transcripts that contain exon 1a (Figure 5b, upper panel) . In contrast, however, idarubicin treatment resulted in massive (8-to 10-fold) induction of the same WRAP53 transcripts (Figure 5b, upper panel) . This pronounced increase in WRAP53 RNA levels coincides with the failure of idarubicin to augment the levels of mature p53 mRNA. An even stronger (10-to 15-fold) upregulation of WRAP53 1a was observed in response to treatment with etoposide ( Figure 5b , lower panel), a topoisomerase II inhibitor that also failed to induce the expression levels of p53. Notably, the amounts of transcripts containing exons 7 and 8 of WRAP53 remained largely unaffected by all of these drugs (Figure 5b ), arguing that the majority of WRAP53 mRNAs start from alternative transcription initiation sites (Figure 5a ) that do not respond to chemotherapy. Taken together, these findings suggest that the abilities of different topoisomerase Figure S4C . Although all four anthracyclines induced TAp73 mRNA, idarubicin failed to increase the levels of p53 mRNA. In contrast, daunorubicin, doxorubicin and epirubicin each induced p53 mRNA to a statistically significant extent. For statistical analysis, a Student's t-test was performed (a ¼ 0.05). (c) U251 cells were treated with 500 nM dauno-, doxo-, epi-, idarubicin, 2.87 mM camptothecin, 100 mM etoposide or 500 mM 5-fluorouracil. Total cell lysates were subjected to immunoblot analysis using antibodies against p53 (Do-1) and HSC70 as loading control. In line with the mRNA expression analysis (a, b), we found p53 protein levels augmented upon dauno-, doxo-and epirubicin treatment, but none of the other tested drugs. (d) Mutant p53 depletion renders the cells more sensitive to doxorubicin treatment. U251 cells were siRNA transfected for 40 h and additionally treated with 500 nM doxo-or idarubicin for the last 4 h, before their seeding in a 96-well imaging plate. The confluence per well was determined regularly for the next 400 h using a cytometer. Means and s.d's of four separate wells per sample are diagramed.
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein inhibitors to induce the accumulation of p53 mRNA or WRAP53 exon 1a RNA are inversely correlated (Table 1) .
To investigate whether WRAP53 mRNA might itself affect the levels of p53, we performed knockdown studies using two different siRNAs to WRAP53, In contrast, doxorubicin only mildly affected the expression of WRAP53. (c) The majority of the WRAP53-1a transcripts reside in the nucleus. U251 cells were treated with 500 nM idarubicin for 24 h. Total cell lysates were subjected to a nuclear-cytoplasmic fractionation and total RNA was isolated from both fractions. Quantitative RT-PCR was used to quantify the expression of the various WRAP53 transcripts. Means and s.d.'s of the nuclear RNA levels relative to the cytoplasmic expression in three biological replicates are depicted. The purity of both fractions (C, cytoplasmic; N, nuclear) was determined by immunoblotting using antibodies against a-tubulin (cytoplasmic) and histone H2B (nuclear). (d) Overexpression of WRAP53-1a results in decreased p53 protein levels. U251 cells were transiently transfected with 20 ng GFP and 180 ng of plasmids expressing WRAP53-1a, shRNA targeting p53 (pSUPER p53) or an empty vector control. Samples in the lower panel were additionally treated with 500 nM doxorubicin for 24 h. Nuclear p53 protein levels were determined using quantitative imunofluorescence analysis. Means and s.d.'s of average p53 expression levels in all cells displaying GFP-fluorescence over background from six separate wells per sample are depicted.
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein targeting exons 2 or 8, respectively. Despite efficient knockdown, this did not grossly interfere neither with p53 mRNA levels (Supplementary Figure S5B) nor with the accumulation of mutant p53 protein (Supplementary Figure S5C) . Thus, at least the most abundant WRAP53 mRNA species do not detectably alter the expression of p53. However, regardless of the efficient siRNAmediated knockdown of the majority of the WRAP53 transcripts, we still observed the maintained expression of RNA containing the sequence of WRAP53 exon 1a. This RNA species was specifically induced in response to idarubicin treatment (Figure 5b ), but was only weakly affected by the two siRNAs (Supplementary Figure  S5B , lower panel). On the basis of these considerations, we suspected that a large proportion of the RNAcontaining WRAP53 exon 1a is not accessible to siRNA. In agreement, cell fractionation and quantitative RT-PCR revealed that RNA corresponding to WRAP53 exon 1a resides in the nucleus (Figure 5c ), thus, explaining its resistance to siRNA-mediated knockdown. It thus seems that the production of this immature WRAP53 transcript from the opposite strand of TP53 interferes with p53 mRNA synthesis or processing. Such a scenario would explain the reciprocal induction of p53 mRNA versus WRAP53 exon 1a by different drugs. Furthermore, plasmid-based overexpression of RNA that contains this exon reduced the amounts of mutant p53, as determined by quantitative immunofluorescence (Figure 5d ). Interestingly, U2OS cells (containing wild-type p53) only mildly increased p53 mRNA levels in response to doxorubicin, whereas they responded with a strong induction of its natural antisense transcript WRAP53 exon 1a RNA (Supplementary Figure S5D) . Thus, the choice of strands regarding transactivation may not be uniform between cell species; it is conceivable that tumor cells with mutant p53 specifically evolve to increase the transcription of p53 mRNA in response to genotoxic stress.
Taken together, we propose that the expression of mutant p53 in response to topoisomerase II inhibition is regulated on at least two levels. We first showed that the transcription factors E2F1 and TAp73 contribute to augmented p53 mRNA levels and that E2F1 associates with TP53 promoter DNA. Second, idarubicin and etoposide fail to increase p53 mRNA levels, but strongly induce the expression of WRAP53 transcripts that contain exon 1a. As WRAP53 1a and the 5 0 -end of the p53 mRNA are encoded by the opposite DNA strands of the same chromosomal region, it is conceivable that WRAP53 1a synthesis interferes with p53 mRNA accumulation.
Discussion
Our results reveal that a widely used class of chemotherapeutics can govern the expression of the most frequently mutated tumor suppressor, through enhanced mRNA levels. As accumulated mutant p53 can contribute to tumor progression and chemoresistance, this raises a caveat about the use of certain anthracyclines for treatment of tumors with p53 mutations.
Mechanisms of mutant p53 accumulation in response to anthracycline treatment Anthracyclines, like other chemotherapeutics, induce a DNA damage response. This response increases E2F1 activity and TAp73 transcription Stiewe and Putzer, 2000) . SiRNA-mediated knockdown, as well as our ChIP studies, revealed that E2F1 binds and activates the promoter of TP53. DNA damage does not necessarily enhance the association of E2F1 with promoter DNA (Figure 3 ), but appears to increase transactivation through posttranslational modifications within E2F1 (Pediconi et al., 2003) , resulting in differential interactions with coactivators . In addition to E2F1 itself, E2F1-induced TAp73 also augments TP53 transcription (Figure 2d ), as expected (Wang and El-Deiry, 2006) . Thus, E2F1 contributes to the doxorubicin-mediated induction of TP53 through direct as well as indirect mechanisms.
However, this does not imply that E2F1 activity is sufficient to increase p53 mRNA levels. Idarubicin and etoposide represent examples of drugs that efficiently induce E2F1 activity and TAp73 levels, but nevertheless fail to augment p53 mRNA. We propose that the DNA binding characteristics of different anthracycline-topoisomerase complexes may ultimately decide about the levels of mutant p53 mRNA. Anthracyclines were shown to intercalate within cellular DNA, and their sequence specificities display subtle differences depending on the particular substitutions within the chemical basic structure (Cashman and Kellogg, 2004) . We propose that the complexes of anthracyclines and topoisomerase II interact with differential sites within the DNA of TP53, enabling enhanced TP53 transcription in a drug-specific manner.
Induction of WRAP53 by a subset of topoisomerase inhibitors Remarkably, one group of anthracyclines (doxorubicin, daunorubicin, epirubicin) efficiently enhanced p53 mRNA levels, but only weakly increased WRAP53 expression. Other topoisomerase inhibitors (idarubicin, etoposide) did not show p53 induction, but elicited a more than 10-fold increase in WRAP53 ( Figure 5 ). This observation is at least compatible with the idea that 
Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein WRAP53 transcription interferes with the synthesis and/or processing of p53 mRNA. Although the ectopic overexpression of WRAP53 mRNA was previously reported to stabilize p53 mRNA in different cell systems (Mahmoudi et al., 2009) , we found that at least WRAP53 RNA corresponding to exon 1a suppressed the levels of mutant p53 (Figure 5d) . It is very possible that the transcription of opposite DNA strands from the same chromosomal region results in negative interference, resulting in the reduction of p53 mRNA in response to endogenous WRAP53 transcription. Such interference phenomena of naturally occurring antisense genes were observed and explained in different ways. First, the physical clash of RNA polymerases may decrease the efficiency of transcription. Second, antisense mRNAs were suggested to promote the methylation of sense mRNA promoters. And third, the formation of double-stranded RNA hybrids may interfere with further mRNA processing (Wutz et al., 1997; Lai, 2002; Prescott and Proudfoot, 2002; Tufarelli et al., 2003; Lavorgna et al., 2004; Crampton et al., 2006) . These models are not mutually exclusive, and more than one of them may apply to the situation of p53 and WRAP53.
Potential consequences for tumor progression
The increase in mutant p53 levels is an undesired effect of anthracycline treatment. These drugs-in particular doxorubicin-are widely used for the treatment of cancer patients. It is conceivable that this treatment, if not successful in killing a tumor cell, may instead promote the mutant p53-associated gain of function. As a consequence, the cells may become more resistant to further cycles of genotoxic therapy (Blandino et al., 1999; Bush and Li, 2002) . Mutant p53 gain of function would also include cell spread, invasion and metastasis (Heinlein et al., 2008; Adorno et al., 2009; Muller et al., 2009; Wang et al., 2009) . Although difficult to prove, the possibility of enhanced tumor progression should be taken into consideration. It is intriguing that idarubicin not only fails to induce mutant p53 expression, but it is also less capable of inducing the drug resistance gene MDR1 to synthesize P-glycoprotein, as compared with other anthracyclines (Hargrave et al., 1995; Lotfi et al., 2002) . Perhaps, similar mechanisms induce MDR1 and TP53 upon anthracycline treatment. The lack of induction by idarubicin observed for both genes may contribute to more efficient tumor cell elimination.
Taken together, this concept raises the possibility that a careful choice of drugs-for example, idarubicin instead of doxorubicin-may avoid the increase in mutant p53 levels and thus lead to a more favorable outcome. Strategies to decrease the levels of mutant p53 for the support of cancer treatment have long been discussed (Blandino et al., 1999; Di Agostino et al., 2006; Lozano, 2007; Strano et al., 2007) . The present study raises the perspective that some established cancer drugs have the opposite effect. This makes it even more desirable to target mutant p53 and counteract its gain of function.
Materials and methods
Cell culture, transfection and drug treatment U251, MDA-MB-231, A431 and 5637 cells were grown in RPMI medium containing 10% fetal bovine serum, 50 U/ml penicillin, 50 mg/ml streptomycin, 200 mM glutamine, 2 mg/ml tetracycline and 10 mg/ml ciprofloxacine. U2OS cells were cultured in Dulbecco's modified Eagle's medium containing the same additions as above. Cells were reverse transfected with siRNAs (pre-designed Silencer Select siRNAs from Applied Biosystems, Carlsbad, CA, USA) using Lipofectamine 2000 (Invitrogen, Paisley, UK). For long-term knockdown (5 days), the cells were reverse transfected as described above. At 48 h later, they were trypsinized and subjected to a second reverse siRNA transfection with 72 h of incubation. For overexpression experiments, the cells were seeded 12-16 h before their transfection with Lipofectamine 2000 (Invitrogen) and the following plasmids: pcDNA3 (Invitrogen), pSUPERshp53 was obtained from C Bamberger (Heidelberg) and CMV-Wrap53-E1aS was kindly provided by K Wiman. Chemotherapeutic treatment of the cells was performed using 500 nM doxorubicin, daunorubicin, epirubicin, idarubicin, 100 mM etoposide, 2.87 mM camptothecin or 500 mM 5-fuorouracil for 24 h each, if not indicated otherwise.
Immunoblot analysis
Proteins were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. This was followed by incubation with antibodies diluted in phosphate-buffered saline (PBS) containing 5% milk powder and Tween-20 (0.1%). The following primary antibodies were used: mouse anti-p53-HRP (DO-1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-P(Ser15)-p53 (16G8, Cell Signaling, Danvers, MA, USA), anti-Ac(Lys382)-p53 (Cell Signaling), anti-E2F1 (KH95 & KH129, Santa Cruz Biotechnology), anti-p300 (N15, Santa Cruz Biotechnology), anti-Mdm2 (Ab-1, Calbiochem, Darmstadt, Germany), anti-actin (AC-15, Abcam, Cambridge, UK), anti-Hsc-70 (B-6, Santa Cruz Biotechnology). Primary antibodies were detected by a peroxidase-coupled secondary antibody (Jackson, ImmunoResearch Europe, Newmarket, UK) using the Chemoluminescence Imaging System (Intas, Go¨ttingen, Germany). Immunoblot quantifications were performed using the LabImage 1D software (Intas).
High-content immunofluorescence analysis
Cells were seeded into 96-well imaging plates (BD-Falcon, Franklin Lakes, NJ, USA), incubated for 24 h and treated with chemotherapeutics for an additional period of 24 h. Subsequently, the cells were fixed with 4% formaldehyde in PBS. Immunofluorescence staining was performed using the following antibodies: anti-p53 (FL-393 Santa Cruz Biotechnology), anti-P(Ser15)-p53 (16G8, Cell Signaling), AlexaFluor-488 antirabbit (Invitrogen) and the AlexaFluor-488 anti-mouse (Invitrogen), AlexaFluor-546 anti-rabbit (Invitrogen) and Cy5 anti-rabbit (Invitrogen), all at 1:500 dilution in PBS containing 10% v/v fetal calf serum. Nuclei were visualized by doxorubicin staining (at a final concentration of 10 mM) or Hoechst 33342 (at a final concentration of 0.2 mg/ml). Automated microscopy was performed with a Pathway HT Cell Imaging System using AttoVision image acquisition software (BD Biosciences, Franklin Lakes, NJ, USA), and single-cell-based image analysis. All samples were analyzed in triplicate and imaged at different positions in the well.
Gene expression analysis
For mRNA analysis, total RNA was isolated using TRIzol (Invitrogen). The isolated RNA was reverse transcribed using Anthracyclines increase mutant p53 levels M Bug and M Dobbelstein 25 U M-Mul V Reverse Transcriptase (New England Biolabs, Ipswich, MA, USA), 5 mM dT 23 VN primer and 1.5 mM N 9 primer. cDNA samples were analyzed by SYBR Green-based real-time PCR using the following ingredients: 75 mM Tris-HCl (pH 8.8), 20 mM (NH 4 ) 2 SO 4 , 3 mM MgCl 2 , 0.01% Tween-20, 0.25% Triton X-100, 300 mM trehalose, 200 mM dNTPs, 1:80 000 SYBR Green I (Roche, Basel, Switzerland), 0.5 U per reaction Taq DNA polymerase (PrimeTech, Minsk, Belarus) and 300 nM primers.
The following primers were used:
The relative expression was determined using 36B4 as control gene according to the DDC t -method.
Chromatin immunoprecipitation
Cells were treated with 500 nM doxorubicin for 24 h. Chromatin was cross-linked with proteins by 1.42% v/v formaldehyde. The cross-linking was stopped by adding glycine to a final concentration of 138 mM. After washing twice in PBS, the cells were scraped into ChIP buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100, Leupeptin (1 mg/ml), Aprotenin (1 mg/ml), Pepstatin A (1 mg/ml), Pefabloc (1 mM)) and pelleted. The pellets were washed in ChIP buffer once and then resuspended in ChIP buffer. The samples were sonicated three times for 10 min (10 sec on/off) with a Bioruptor sonicator (Diagenode, Lie´ge, Belgium). The supernatant was diluted with ChIP buffer and precleared for 1 h using plain Sepharose (Amersham, Little Chalfont, UK). Antibodies (1 mg) against E2F1 (KH20 and KH95, Upstate, Billerica, MA, USA) were added and incubated overnight at 4 1C. Anti-IgG antibody (Santa Cruz Biotechnology) was used as negative control under the same condition. An input control of each sample was taken for DNA precipitation. The antibody-bound protein-DNA complexes were incubated with Protein A sepharose for 2 h. Immunoprecipitates were washed with ChIP buffer for eight times. After brief centrifugation, the pellet as well as the precipitated input DNA, were resuspended in 10% Chelex (Bio-Rad, Hercules, CA, USA) and digested with Proteinase K (200 ng/ml) for 30 min at 55 1C, followed by incubation at 95 1C for 10 min. The samples were pelleted, and 1 ml of the supernatant was used for quantitative PCR with the following primers.
Cell fractionation
The cells were seeded in 16 cm cell culture dishes and subsequently treated with 500 nM doxorubicin for 24 h. The cells were washed in ice-cold PBS twice before they were lysed in 3 ml fractionation buffer (50 mM Tris HCl pH 7.5, 140 mM NaCl, 1.5 mM MgCl 2 , 0.5% Nonidet P-40, 500 U/ml RNAse inhibitor (NEB)) for 10 min at 4 1C. The cells were scraped, transferred into 2 ml tubes and centrifuged for 10 min at 900 r.p.m. at 4 1C. The supernatant (cytoplasmic fraction) is kept on ice for the subsequent RNA isolation, whereas the pellet was washed twice in fractionation buffer. The DNA was extracted from the nuclear pellets and from the cytoplasmic fraction using TRIzol (Invitrogen).
Adherent cell cytometer analysis
The cells were siRNA transfected in 12-well cell culture plates. At 36 h later, the cells were treated with 500 nM doxorubicin or idarubicin. After 4 h the drug was removed and the cells were trypsinized. In total, 2500 cells of the control siRNA-transfected, doxorubicin-treated sample and equal volumes of the other samples were seeded in a 96-well imaging plate (Corning, Amsterdam, Netherlands). Cell confluence was determined regularly for 16 days using the Celigo Cell Cytometer (Cyntellect, San Diego, CA, USA). 
